Navigation Links
CutisPharma Launches New Prescription Mouthwash Kit Adding to Product Line
Date:9/22/2009

WOBURN, Mass., Sept. 22 /PRNewswire/ -- CutisPharma, Inc. announced the introduction of FIRST(R) - BXN Mouthwash. It is the second in the FIRST(R) Mouthwash Compounding Kit product line, which already includes FIRST(R) - Mouthwash BLM. The active ingredients in FIRST(R) - BXN Mouthwash are comparable to those found in the most routinely prepared formulation of Magic Mouthwash containing Benadryl(R), Xylocaine 2% viscous(R), and nystatin. The kits are made for one patient and include pre-weighed diphenhydramine hydrochloride, lidocaine hydrochloride, and nystatin powder, and a pre-measured suspension. With FIRST(R) - BXN Mouthwash, the pharmacist needs only to add the powders to the liquid suspension, shake, and then dispense to the patient.

"By launching FIRST(R) - BXN, physicians now have two of the more commonly prescribed magic mouthwash prescriptions available in a kit," said Dr. Indu Muni, founder, chairman, and CEO of CutisPharma, Inc. "The Company anticipates launching two additional Mouthwash products, FIRST(R) - Mary's Mouthwash, and FIRST(R) - Duke's Mouthwash, in the near future, thus completing the Mouthwash product line."

FIRST(R) products save dispensing time, and can be compounded by the pharmacist while the patient waits, increasing customer satisfaction. Using FIRST(R) Mouthwash kits, the pharmacist can compound a prescription faster than those prepared in the conventional way. A single NDC number assigned for the entire Kit facilitates the third party reimbursement process, and reduces audit- related adjustments.

CutisPharma now has ten proprietary prescription compounding kits on the market: five progesterone suppository compounding kits, two testosterone kits, one hydrocortisone kit, and two Magic Mouthwash kits. Several more compounding kits are in the planning stages. FIRST((R)) Unit-of-Use Prescription Compounding Kits comply with United States Pharmacopeia (USP) Chapter <795>.

The FDA estimates that each year in the United States approximately 30 million retail and hospital outpatient prescriptions are prepared through "compounding," a means by which a pharmacist prepares a customized medication according to a doctor's prescription to meet an individual patient's medical need. About 1% of all prescriptions are compounded; and the U.S. market alone for compounding, at the consumer level, represents an estimated $1 billion annually.

About CutisPharma

CutisPharma, Inc. based in Woburn, MA, is a privately held, specialty pharmaceutical company focusing on the development and commercialization of value-added proprietary drug products and technologies in the prescription compounding sector of the pharmaceutical industry. Product line and development efforts initially are focused on providing optimized, more efficient alternatives for the preparation of the nearly 10 million currently compounded prescriptions, by offering FIRST(R) Unit-of-Use Prescription Compounding Kits. Use of these branded compounding kits will be beneficial to all triad participants, namely physicians, pharmacists, and patients. Two U.S. patents have been issued to the Company with several additional patents pending.

For more information please visit our website at www.cutispharma.com


'/>"/>
SOURCE CutisPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. RESOLVE: The National Infertility Association Announces Partnership With CutisPharma
2. CutisPharma Announces Issuance of a Patent for Suppository Compounding
3. CutisPharma Announces Strategic Collaboration with Rite Aid Corporation
4. CutisPharma Selected by Medicine Shoppe International as Preferred Vendor for Unit-of-Use Compounding Kits
5. MEDISON Launches New Dedicated OB/GYN 3D/4D Ultrasound System, ACCUVIX V20 Prestige
6. Webmedx Launches New Data-Mining Solution for Medical Transcription and Speech-Generated Documents
7. World Health Organization Launches New Attack on Lung Cancer
8. Thomson Reuters Launches Thomson Pharma Partnering Forecast
9. https://happier.com/form.htmhappier.com Launches a Personal Trainer for Your Happiness
10. American Lung Association Launches Retro Marketing Initiative to Support 2009 Christmas Seals(R) Campaign
11. LYSOL(R) Launches Healthier Habits Rewards Program at Schools Nationwide to Help Protect Families from Germs, Such as H1N1
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Qrono Inc. , ... a development collaboration with the Australian critical medicine company, Phebra Pty Ltd. ... , LAI medicines can offer improved therapeutic benefits over oral formulations, including better ...
(Date:5/5/2016)... ... May 05, 2016 , ... The ... electronic cigarettes, requiring e-cigarette manufacturers to submit their products through an arduous federal ... all vaping products that entered the market since February 15, 2007. That would ...
(Date:5/5/2016)... FL (PRWEB) , ... May 05, 2016 , ... ... in Tampa to offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to ... Implant. Since first offering the procedure in April of 2015, Florida Hospital Pepin ...
(Date:5/5/2016)... ... May 05, 2016 , ... This weekend, from Friday, May 6 - Sunday, May 8, ... terrain at the first Team Semper Fi Mountain Bike Camp, hosted in conjunction with ... bike legends Mark Weir and Jason Moeschler, who’ll share pro tips with the injured veterans ...
(Date:5/5/2016)... ... 2016 , ... Phycologia – While it is ... researchers Juntian Xu and Kunshan Gao tested the magnitude of this phenomenon on ... photosynthetically active radiation (i.e. the white light in our visible spectrum) was not ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... 2016 Research and ... Acute lymphocytic Leukemia Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Market and Competitive Landscape Highlights 2016, provides ... products, Acute Lymphocytic Leukemia epidemiology, Acute Lymphocytic ...
(Date:5/3/2016)... DUBLIN , May 4, 2016 ... the "Global Cancer Stem Cell Therapy Market Outlook ... (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,Recombinant technology has ... therapeutics are expected to be developed in coming years. ... these techniques. Cancer stem cell therapies are also expected ...
(Date:5/3/2016)... , May 3, 2016 ACME ... Whelan and Delaware County Councilman ... Nasal Spray in all ACME pharmacies across ... for Disease Control and Prevention (CDC), naloxone has saved 26,463 lives ... officers in Delaware County were authorized to ...
Breaking Medicine Technology: